Tevogen Bio Strengthens Leadership with Appointment of David E. Banko

Tevogen Bio has named David E. Banko, CPA, a seasoned expert in market access and health policy, as its Global Head of Government Affairs and Patient Access. With over 30 years of experience in pharmaceuticals, medical devices, and diagnostics—including key roles at Cordis (a former Johnson & Johnson company) and B. Braun Medical Inc.—Banko brings extensive expertise in payer engagement, reimbursement strategies, and health policy development. His appointment marks a significant step in Tevogen’s path to commercialization, ensuring its AI-driven immunotherapy innovations reach patients in oncology, virology, neurology, and rheumatology.

Banko will lead market access initiatives, collaborating with R&D and commercial teams to establish coverage, coding, and reimbursement strategies for Tevogen’s therapies. Additionally, he will work with government agencies and private payers to ensure healthcare system readiness for new treatments. Tevogen Bio CEO Dr. Ryan Saadi emphasized Banko’s role in creating a clear value proposition for patients, providers, and policymakers, reinforcing the company’s commitment to advancing innovative, accessible immunotherapies.